Semprana dihydroergotamine regulatory update

Allergan said FDA issued the third complete response letter for a resubmitted NDA for Semprana dihydroergotamine for the acute treatment of migraines in adults. The company said

Read the full 272 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE